Alumis
Alumis Inc. is seeking an experienced Medical Director to lead medical content strategy, scientific readiness, and launch execution for the potential launch of envudeucitinib in dermatology. The role will serve as the primary Medical Affairs lead, translating emerging clinical data into accurate, clinically meaningful resources and collaborating across cross‑functional teams to ensure consistent scientific communication throughout late‑stage development and commercialization.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2021
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for immune-mediated diseases. It advances a late-stage portfolio of next-generation targeted programs — including TYK2 and IGF-1R pathway efforts and assets such as envudeucitinib and lonigutamab — aimed at conditions like psoriasis, SLE and thyroid eye disease. The company combines integrated scientific insights with a proprietary data‑analytics platform to guide therapeutic development and clinical trial strategy. Alumis emphasizes patient-centered development, offering resources and conducting trials to translate its medicines into meaningful improvements in patients’ lives.
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead
2 days ago
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026
20 hours ago
Raymond James initiates Alumis stock coverage citing psoriasis drug potential
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Alumis.
8% below the average for this role
Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock
Jan 9, 2026
Senior Medical Director, Medical Affairs
Latigobio
Vice President, Medical Affairs, Hematology-Oncology
Nurix
Associate Director, Scientific Communications
Compass Pathways
Medical Science Liaison (MSL) / Senior Medical Science Liaison (Sr. MSL)
Celldex Therapeutics
Regional Medical Science Liaison Director (RMD), Immunology – East
Celldex Therapeutics
Medical Science Liaison (MSL) / Senior Medical Science Liaison (Sr. MSL)
Celldex Therapeutics